Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586112 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Alumis.
- Active
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
- 20
- Study locations
NCT06586112 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Alumis. The registered enrollment target is 840 participants, above the 397-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (112% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06586112, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Alumis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ESK-001
- DRUG Apremilast
Study Locations (20)
California
- Exalt Clinical Research - Chula Vista
- California Dermatology & Clinical Research Institute - Encinitas
- First OC Dermatology Research Inc - Fountain Valley
- Marvel Clinical Research, LLC - Huntington Beach
- Sunwise Clinical Research, LLC - Lafayette
- Wallace Medical Group Inc - Los Angeles
- Northridge Clinical Trials - Elite Clinical Network - Northridge
- Pasadena Clinical Trials - Pasadena
- Therapeutics Clinical Research - San Diego
- Unison Clinical Trials/ Shahram Jacobs MD - Sherman Oaks
- Olive View - UCLA Education & Research Institute - Sylmar
- California Dermatology Institute - Thousand Oaks - Thousand Oaks
Florida
- Clearlyderm Dermatology - West Boca Raton - Boca Raton
- Driven Clinical Research - Coral Gables
- Jacksonville Center for Clinical Research - Jacksonville
- Glick Skin Institute - Margate - Margate
- San Marcus Research Clinic, Inc - Miami - Miami Lakes
Arizona
- Alliance Dermatology - Phoenix
- Scottsdale Clinical Trials - Scottsdale
Arkansas
- Northwest Arkansas Clinical Trials Center (NWACTC), PLLC - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06586112
The ClinicalTrials.gov registry entry for NCT06586112 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 397-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (112% higher). The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06586112 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06586112 about?
NCT06586112 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis". The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study include...
What is the current status of trial NCT06586112?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2024-07-25. Estimated completion is 2025-12.
What conditions does trial NCT06586112 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06586112?
The interventions under investigation include: Placebo (DRUG), ESK-001 (DRUG), Apremilast (DRUG).
Who is sponsoring clinical trial NCT06586112?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586112 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.